Published Articles Written by LLNielsen Medical Writing LLC
Thompson CC, et al. Stoma size is critical to 12-month outcomes in endoscopic suturing for gastric bypass repair. Surg Obes Relat Dis 2011. Epub April 19th. (USGI Medical)
Liu Q, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010;9:76 (Amylin Pharmaceuticals)
Liu Q, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010;9:32 (Amylin Pharmaceuticals)
Gersin KS, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endoscopy 2010;71:976-982 (GI Dynamics)
Escalona A, et al. Initial human experience with restrictive duodenal-jejunal bypass liner for treatment of morbid obesity. Surg Obes Related Dis 2010;6:126-131 (GI Dynamics)
Rodriguez L, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diab Tech Ther 2009;11:725-732 (GI Dynamics)
Wilcox CS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addictive Behaviors 2010;35:229-234 (Orexigen Therapeutics)
Published Posters by LLNielsen Medical Writing LLC
O’Neil PM, et al. Randomized, placebo-controlled trial of lorcaserin for weight loss in patients with type 2 diabetes. Annual Meeting of the American Diabetes Association, June 2011. Diabetes 2011;60 (Suppl 1):A507 (1878-P) (Arena Pharmaceuticals)
Fidler MC, et al. Lorcaserin, a selective 5-HT2C agonist, evaluated as a weight loss agent in obese and overweight patients with type 2 diabetes treated with sulfonylureas or metformin. Annual Meeting of the American Diabetes Association, June 2011. Diabetes 2011;60 (Suppl 1):A515 (1908-P) (Arena Pharmaceuticals)
++++++++++++++++++++++++++++++++++++++++++++++++++++++
Authored Articles & Reviews
Health Outcomes
McAdam-Marx C, et al. Diab Obes Metab 2010
Brixner DI, et al. Diab Obesity Metab 2009;11:1122-1130
Fabunmi R, et al. Curr Med Res Opin 2009;25:777-786
Diabetes Therapy
Nielsen LL, , et al. J Diab Sci Tech 2008;2:255-260
Gedulin BR, , et al. Int J Pharmaceutics 2008;356: 231-238
Klonoff DC, et al. Curr Med Res Opin 2008;24:275-286
Buse JB, et al. Clin Ther 2007;29:139-153
Mari A, et al. Horm Metab Res 2006;38:838-844
Hinnen D, et al. J Amer Board Family Med 2006;19:612-620
Ratner RE, et al. Diabetes Obes Metab 2006;8:419-428
Copley K, et al. Curr Drug Metab 2006;7:367-374
Fehse F, et al. J Clin Endocrinol Metab 2005;90:5991-5997
Taylor K, et al. Horm/Metab Res Rev 2005;37:627-632
Gedulin BR, et al. Diabetologia 2005;48:1380-1385
Nielsen LL. Drug Discovery Today 2005;10: 703-710
Gedulin BR, et al. Endocrinol 2005;146:2069-2076
Kolterman OG, et al. Amer J Hlth-Syst Pharmacy 2005;62:173-181
Nielsen LL, et al. Regulatory Peptides 2004;117:77-88
Nielsen LL, et al. Curr Opinion Invest Drugs 2003;4:401-405
